

**Supporting Information**

**Direct Hiyama Cross-Coupling of Enaminones With  
Triethoxy(aryl)silanes and Dimethylphenylsilanol**

**Lei Bi and Gunda I. Georg**

*Department of Medicinal Chemistry, University of Kansas, 1251 Wescoe Hall Drive, Lawrence,  
Kansas 66045, Department of Medicinal Chemistry and the Institute for Therapeutics Discovery and  
Development, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414  
georg@umn.edu*


Materials and Methods	p S2
Experimental Procedures	p S2
Spectra	p S8

## Materials and Methods


Palladium (II) acetate and other chemicals and solvents were commercially available. Flash column chromatography was carried out on silica gel. TLC was conducted on silica gel 250 micron, F254 plates. <sup>1</sup>H NMR spectra were recorded at 400 MHz. Chemical shifts are reported in ppm with the solvent as the internal standard (CDCl<sub>3</sub>: 7.26 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants (Hz) and integration. <sup>13</sup>C NMR spectra were recorded at 100 MHz NMR with complete proton decoupling. Chemical shifts are reported in ppm with the solvent as internal standard (CDCl<sub>3</sub>: 77.2 ppm).

The starting enaminones were prepared using the method reported by Comins.<sup>1</sup> Compound **1f** was prepared according to our previous report.<sup>2</sup> Enaminones **1a**,<sup>2,3</sup> **1b**,<sup>4</sup> **1c**,<sup>2,3</sup> **1f**,<sup>4</sup> **1h**,<sup>1</sup> and 2,3-dihydropyridin-4(1*H*)-one<sup>5</sup> are known compounds and enaminone **1g** is commercially available.

## Experimental Procedures




**1-(3-(tert-Butyldimethylsilyloxy)propyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (1d).** Into a solution of 2-phenyl-2,3-dihydropyridin-4(1*H*)-one<sup>3</sup> (450.0 mg, 2.60 mmol) in THF (25 mL) at -78 °C was added a 1.6 M solution of <sup>n</sup>BuLi in hexane (2.0 mL, 3.20 mmol) dropwise under a N<sub>2</sub> atmosphere. After 15 min, (3-bromopropoxy)-tert-butyldimethylsilane (1.2 mL, 5.18 mmol) was dropwise added into the reaction. The reaction was stirred for another 30 min at -78 °C and then warmed up to room temperature over a course of 24 h. After the solvent was removed under reduced pressure, water (15 mL) was added and then the mixture was extracted with EtOAc (10 mL × 3). The combined organic layers were washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. Further purification was carried out by flash column chromatography (60% EtOAc/hexane) to produce 285.0 mg (32%) of **2** as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37–7.23 (m, 5H), 7.17 (d, *J* = 7.6 Hz, 1H), 5.00 (d, *J* = 7.6 Hz, 1H), 4.60 (t, *J* = 7.4 Hz, 1H), 3.58 (t, *J* = 5.5 Hz, 2H), 3.34–3.22 (m, 1H), 3.20–3.08 (m, 1H), 2.85 (dd, *J* = 16.4, 7.0 Hz, 1H), 2.66 (dd, *J* = 16.4, 7.9 Hz, 1H), 1.71–1.60 (m, 2H), 0.84 (s, 9H), 0.00 (s, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 190.2, 154.6, 138.9, 129.1, 128.4, 127.0, 98.2, 61.1, 59.3, 50.2, 43.9, 31.5, 26.0, 18.3, -5.3; HRMS (ESI+) calcd for [M+H]<sup>+</sup> C<sub>20</sub>H<sub>32</sub>NO<sub>2</sub>Si 346.2202, found 346.2185.




**1-(2-Bromobenzyl)-2-methyl-2,3-dihydropyridin-4(1H)-one (1e).** 1-(2-Bromobenzyl)pyridin-4(1H)-one (1500.0 mg, 5.68 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (20 mL) was treated with TMSOTf (2.4 mL, 13.26 mmol) at room temperature under a  $\text{N}_2$  atmosphere. After the reaction was stirred for 1 h, 2,6-lutidine (1.5 mL, 12.88 mmol) was added, followed by the slow addition of a 3 M solution of methylmagnesium bromide in diethyl ether (4.0 mL, 12.00 mmol) using a syringe pump. The reaction was stirred for another 2 hours and then quenched with saturated  $\text{NH}_4\text{Cl}$  (10 mL). The mixture was extracted with  $\text{CH}_2\text{Cl}_2$  (10 mL  $\times$  4). The combined organic layers were washed with saturated NaCl, dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure. Further purification was carried out by flash column chromatography (99% EtOAc with 1%  $\text{Et}_3\text{N}$ ) to produce 72.9 mg (5%) of **1e** as a yellow wax.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.60 (dd,  $J = 7.9, 0.9$  Hz, 1H), 7.39–7.29 (m, 2H), 7.21 (td,  $J = 7.6, 2.0$  Hz, 1H), 6.98 (d,  $J = 7.5$  Hz, 1H), 4.97 (d,  $J = 7.5$  Hz, 1H), 4.51 (d,  $J = 15.6$  Hz, 1H), 4.39 (d,  $J = 15.6$  Hz, 1H), 3.69–3.56 (m, 1H), 2.77 (dd,  $J = 16.3, 6.7$  Hz, 1H), 2.21 (dd,  $J = 16.3, 3.7$  Hz, 1H), 1.24 (d,  $J = 6.6$  Hz, 3H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  190.8, 152.5, 135.6, 133.6, 130.0, 129.5, 128.1, 123.8, 97.8, 57.1, 52.4, 42.5, 15.0; HRMS (ESI+) calcd for  $[\text{M}+\text{H}]^+$   $\text{C}_{13}\text{H}_{15}\text{NOBr}$  280.0337, found 280.0335.

**General Procedures for the Palladium (II)-Catalyzed Oxidative Hiyama Coupling of Enaminones.** All reactions were run at the 0.2 mmol (enaminone) scale. The suspension of the enaminone (0.2 mmol) and palladium acetate (12 mg, 0.050 mmol) in a mixture of *tert*-butyl alcohol and acetic acid (4:1, 1 mL) were stirred at 65 °C for 15 min. The suspension of the corresponding siloxane (0.5 mmol) and cupric fluoride (252 mg, 0.5 mmol) in a mixture of *tert*-butyl alcohol and acetic acid (4:1, 1 mL) were stirred at room temperature for 30 min. The two suspensions then were mixed and allowed to stir at 65 °C for another 3 h. The reaction mixture was cooled to room temperature, filtered through a silica gel pad, and washed with ethyl acetate. The volatiles were removed *in vacuo*. The crude product was purified by silica gel flash chromatography (hexanes/ethyl acetate) to afford the corresponding title compound.




***N*-Benzyl-2,5-diphenyl-2,3-dihydropyridin-4(1H)-one (3a).** **Method A**, refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (53 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 56 mg (82%) of the title compound was obtained as an oil. **Method B**, refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (53 mg, 0.20 mmol) was reacted with dimethylphenylsilanol (76 mg, 0.50 mmol) and 54 mg (80%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.57 (s, 1H), 7.44 (d,  $J = 8.2$


Hz, 2H), 7.35 (m, 13H), 4.57 (t,  $J = 7.4$  Hz, 1H), 4.43 (d,  $J = 15.1$  Hz, 1H), 4.17 (d,  $J = 14.8$  Hz, 1H), 2.97 (dd,  $J = 16.3$  Hz, 7.0 Hz, 1H), 2.83 (dd,  $J = 16.1$  Hz, 7.6 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.6, 153.3, 138.4, 136.1, 135.9, 129.1 (2C), 129.0 (2C), 128.5(2C), 128.3, 128.2 (2C), 127.8 (2C), 127.7 (2C), 127.1, 125.8, 111.3, 60.8, 57.7, 44.3; HRMS (ESI) calcd for  $\text{C}_{24}\text{H}_{22}\text{NO}$   $[\text{M}+1]^+$  340.1701, found 340.1685.



***N*-Benzyl-2-phenyl-5-(4'-tolyl)-2,3-dihydropyridin-4(1H)-one (3b)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (53 mg, 0.20 mmol) was reacted with triethoxy(4-tolyl)silane (127 mg, 0.500 mmol) and 60 mg (85%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.47 (s, 1H), 7.28 (m, 11H), 7.12 (m, 3H), 4.48 (t, 7.6 Hz, 1H), 4.34 (d,  $J = 15.1$  Hz, 1H), 4.12 (d,  $J = 15.1$  Hz, 1H), 2.91 (dd,  $J = 16.2$  Hz, 6.9 Hz, 1H), 2.75 (dd,  $J = 16.3$  Hz, 8.0 Hz, 1H), 2.24 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.8, 153.0, 138.5, 135.9, 135.4, 133.0, 129.1 (2C), 129.0 (2C), 128.9 (2C), 128.4, 128.3 (2C), 127.8 (2C), 127.7 (2C), 127.1, 111.4, 60.9, 57.6, 44.3, 21.1; HRMS (ESI) calcd for  $\text{C}_{25}\text{H}_{24}\text{NO}$   $[\text{M}+1]^+$  354.1858, found 354.1872.




***N*-Benzyl-2-phenyl-5-(4'-(trifluoromethyl)phenyl)-2,3-dihydropyridin-4(1H)-one (3c)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (53 mg, 0.20 mmol) was reacted with triethoxy(4-(trifluoromethyl)phenyl)silane (154 mg, 0.500 mmol) and 59 mg (73%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.63 (s, 1H), 7.56 (m, 4H), 7.36 (m, 6H), 7.25 (d,  $J = 8.3$  Hz, 2H), 7.20 (d,  $J = 8.2$  Hz, 2H), 4.59 (t,  $J = 7.2$  Hz, 1H), 4.48 (d,  $J = 15.0$  Hz, 1H), 4.25 (d,  $J = 15.1$  Hz, 1H), 3.02 (dd,  $J = 16.3$  Hz, 7.2 Hz, 1H), 2.83 (dd,  $J = 16.3$  Hz, 7.2 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.3, 153.4, 139.7, 138.0, 135.4, 129.2 (2C), 129.1 (2C), 128.6 (2C), 128.5, 127.8 (2C), 127.4 (2C), 126.9 (2C), 125.1, 125.1, 125.0, 109.7, 0.6, 57.9, 44.0; HRMS (ESI) calcd for  $\text{C}_{25}\text{H}_{21}\text{F}_3\text{NO}$   $[\text{M}+1]^+$  408.1575, found 408.1558.




***N*-Benzyl-5-(4'-methoxyphenyl)-2-phenyl-2,3-dihydropyridin-4(1H)-one (3d)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (53 mg, 0.20 mmol) was reacted with triethoxy(4-methoxyphenyl)silane (135 mg, 0.500 mmol) and 37 mg (50%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.49 (s, 1H), 7.35 (m, 7H), 7.27 (m, 3H), 7.16 (d,  $J =$


7.7 Hz, 2H), 6.89 (d,  $J = 8.8$  Hz, 2H), 4.55 (t,  $J = 7.6$  Hz, 1H), 4.42 (d,  $J = 15.1$  Hz, 1H), 4.19 (d,  $J = 15.1$  Hz, 1H), 3.80 (s, 3H), 2.98 (dd,  $J = 16.3$  Hz, 6.9 Hz, 1H), 2.83 (dd,  $J = 16.3$  Hz, 8.2 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.9, 157.9, 152.8, 138.5, 135.9, 129.1 (2C), 129.0 (2C), 128.9 (2C), 128.5, 128.4, 128.3, 127.7 (2C), 127.1 (2C), 113.7 (2C), 111.2, 60.9, 57.5, 55.3, 44.3; HRMS (EI) calcd for  $\text{C}_{25}\text{H}_{24}\text{NO}_2$   $[\text{M}+1]^+$  370.1807, found 370.1788.



***N*-Benzyl-5-(4'-chlorophenyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (3e)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (53 mg, 0.20 mmol) was reacted with triethoxy(4-chlorophenyl)silane (137 mg, 0.500 mmol) and 49 mg (65%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.55 (s, 1H), 7.36 (m, 8H), 7.27 (m, 4H), 7.16 (d,  $J = 7.7$  Hz, 2H), 4.56 (t,  $J = 7.3$  Hz, 1H), 4.44 (d,  $J = 15.1$  Hz, 1H), 4.22 (d,  $J = 15.1$  Hz, 1H), 2.99 (dd,  $J = 16.3$  Hz, 7.1 Hz, 1H), 2.81 (dd,  $J = 16.3$  Hz, 7.6 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.5, 153.1, 138.2, 135.6, 134.5, 131.3 (2C), 129.2 (2C), 129.1 (2C), 128.8, 128.5, 128.4, 128.3 (2C), 127.7 (2C), 127.0 (2C), 110.1, 60.7, 57.8, 44.1; HRMS (ESI) calcd for  $\text{C}_{24}\text{H}_{21}\text{ClNO}$   $[\text{M}+1]^+$  374.1312, found 374.1337.




***N*-Benzyl-5-(4'-bromophenyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (3f)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (53 mg, 0.20 mmol) was reacted with triethoxy(4-bromophenyl)silane (159 mg, 0.500 mmol) and 51 mg (61%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.55 (s, 1H), 7.42 (dd,  $J = 6.5$  Hz, 1.9 Hz, 2H), 7.35 (m, 8H), 7.25 (dd,  $J = 7.4$  Hz, 2.0 Hz, 2H), 7.16 (dd,  $J = 7.7$  Hz, 2.0 Hz, 2H), 4.56 (t,  $J = 7.3$  Hz, 1H), 4.44 (d,  $J = 15.1$  Hz, 1H), 4.22 (d,  $J = 15.1$  Hz, 1H), 2.99 (dd,  $J = 16.3$  Hz, 7.0 Hz, 1H), 2.81 (dd,  $J = 16.3$  Hz, 7.6 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.5, 153.0, 138.1, 135.6, 134.9, 131.2 (2C), 129.1 (2C), 129.1 (2C), 129.0, 128.5, 128.4 (2C), 127.7 (2C), 127.0 (2C), 119.3, 110.0, 60.7, 57.7, 44.1; HRMS (ESI) calcd for  $\text{C}_{24}\text{H}_{21}\text{BrNO}$   $[\text{M}+1]^+$  418.0807, found 418.0782.




***N*-Benzyl-5-(1'-naphthyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (3g)**. Refer to the general procedure. *N*-Benzyl-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (53 mg, 0.20 mmol) was reacted with trimethoxy(1-naphthyl)silane (124 mg, 0.500 mmol) and 34 mg (43%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.58 (m, 3H), 7.34 (m, 13H), 7.16 (d,  $J = 7.6$  Hz,


2H), 4.68 (t,  $J = 7.5$  Hz, 1H), 4.37 (d,  $J = 14.8$  Hz, 1H), 4.20 (d,  $J = 15.1$  Hz, 1H), 3.08 (dd,  $J = 16.4$  Hz, 7.1 Hz, 1H), 2.94 (dd,  $J = 16.3$  Hz, 8.0 Hz, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.9, 135.9, 134.1, 133.9, 129.2 (2C), 129.1 (2C), 129.0, 128.5, 128.4, 128.3 (2C), 127.9, 127.8, 127.7(2C), 127.2, 127.1, 126.2, 125.8, 125.7, 125.6, 125.5 (2C), 61.0, 57.6, 44.2; HRMS (ESI) calcd for  $\text{C}_{28}\text{H}_{24}\text{NO}$   $[\text{M}+1]^+$  390.1858, found 390.1872.




***N*-Benzyl-5-phenyl-2,3-dihydropyridin-4(1*H*)-one (3h).** Refer to the general procedure. *N*-Benzyl-2,3-dihydropyridin-4(1*H*)-one (37 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 33 mg (62%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.39 (m, 4H), 7.32 (m, 5H), 7.17 (t,  $J = 7.3$  Hz, 2H), 4.43 (s, 2H), 3.44 (t,  $J = 7.7$  Hz, 2H), 2.60 (t,  $J = 7.9$  Hz, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  188.6, 153.2, 136.3 (2C), 135.7, 129.1 (2C), 128.4 (2C), 128.2, 127.8, 127.7 (2C), 125.7, 111.2, 60.2, 46.8, 36.3; HRMS (ESI) calcd for  $\text{C}_{18}\text{H}_{18}\text{NO}$   $[\text{M}+1]^+$  264.1388, found 264.1370.




***N*-Benzyl-2-methyl-5-phenyl-2,3-dihydropyridin-4(1*H*)-one (3i).** Refer to the general procedure. *N*-Benzyl-2-methyl-2,3-dihydropyridin-4(1*H*)-one (40 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 45 mg (81%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34 (m, 4H), 7.25 (m, 6H), 7.07 (t,  $J = 7.4$  Hz, 1H), 4.37 (dd,  $J = 25.8$  Hz, 15.3 Hz, 2H), 3.55 (m, 1H), 2.76 (dd,  $J = 16.1$  Hz, 6.5 Hz, 1H), 2.28 (dd,  $J = 16.0$  Hz, 4.8 Hz, 1H), 1.18 (d,  $J = 6.7$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.0, 150.6, 135.3, 128.0 (2C), 127.3, 127.1 (2C), 126.5, 126.4 (2C), 126.3 (2C), 124.5, 108.8, 56.5, 50.9, 42.1, 14.3; HRMS (ESI) calcd for  $\text{C}_{19}\text{H}_{20}\text{NO}$   $[\text{M}+1]^+$  278.1545, found 278.1561.



***N*-(3'-((*tert*-Butyldimethylsilyloxy)propyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (3j).** Refer to the general procedure. *N*-(3'-((*tert*-Butyldimethylsilyloxy)propyl)-2-phenyl-2,3-dihydropyridin-4(1*H*)-one (69 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 63 mg (75%) of the title compound was obtained as an oil.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45 (s, 1H), 7.42 (d,  $J = 8.2$  Hz, 2H), 7.31 (m, 7H), 7.15 (dd,  $J = 13.4$  Hz, 7.4 Hz, 1H), 4.67 (t,  $J = 7.4$  Hz, 1H), 3.63 (t,  $J = 5.5$  Hz, 2H), 3.38 (m, 1H), 3.24 (m, 1H), 3.02 (dd,  $J = 16.2$  Hz, 6.9 Hz, 1H), 2.82 (dd,  $J = 16.2$  Hz, 7.8 Hz, 1H), 1.71 (m, 2H), 0.84 (s, 9H), -0.01 (d,  $J = 7.0$  Hz, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  187.3, 153.7, 138.6, 136.2, 129.1(2C), 128.3, 128.2 (2C), 127.5(2C), 126.9 (2C), 125.6, 110.7, 61.2, 59.2, 50.5, 44.3, 31.5, 25.8 (3C), 18.2, -5.4 (2C); HRMS (ESI) calcd for  $\text{C}_{26}\text{H}_{36}\text{NO}_2\text{Si}$   $[\text{M}+1]^+$  422.2515, found 422.2501.





***N*-(2'-Bromobenzyl)-2-methyl-5-phenyl-2,3-dihydropyridin-4(1*H*)-one (3k).** Refer to the general procedure. *N*-(2'-Bromo)benzyl-2-methyl-2,3-dihydropyridin-4(1*H*)-one (56 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 48 mg (68%) of the title compound was obtained as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62 (d, *J* = 7.9 Hz, 1H), 7.38 (m, 4H), 7.31 (m, 4H), 7.20 (m, 1H), 4.53 (dd, *J* = 37.6 Hz, 15.5 Hz, 2H), 3.66 (m, 1H), 2.91 (dd, *J* = 16.1 Hz, 6.6 Hz, 1H), 2.37 (dd, *J* = 16.0 Hz, 3.8 Hz, 1H), 1.27 (d, *J* = 6.7 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 188.0, 151.6, 136.2, 135.3, 133.6, 130.0, 129.6, 128.2 (2C), 128.0, 127.6 (2C), 125.6, 123.9, 110.2, 57.5, 52.5, 43.0, 15.3; HRMS (ESI) calcd for C<sub>19</sub>H<sub>19</sub>BrNO [M+1]<sup>+</sup> 356.0650, found 356.0636.




**3-Phenyl-7,8,9,9a-tetrahydro-1*H*-quinolizin-2(6*H*)-one (3l).** Refer to the general procedure. 7,8,9,9a-Tetrahydro-1*H*-quinolizin-2(6*H*)-one (30 mg, 0.20 mmol) was reacted with triethoxy(phenyl)silane (120 mg, 0.500 mmol) and 33 mg (72%) of the title compound was obtained as an oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (d, *J* = 8.8 Hz, 2H), 7.05 (s, 1H), 6.85 (m, 3H), 3.41 (m, 1H), 3.36 (m, 1H), 3.01 (dt, *J* = 2.6, 6.3 Hz, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 1.80 (m, 3H), 1.52 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 194.2, 156.5, 152.9, 128.9 (2C), 128.1, 127.7 (2C), 105.4, 54.9, 51.7, 41.4, 29.8, 23.8, 20.8; HRMS (ESI) cal'd for C<sub>15</sub>H<sub>18</sub>NO [M+1]<sup>+</sup> 228.1388, found 228.1400.

## References:


- (1) Comins, D. L.; Brown, J. D. *Tetrahedron Lett.* **1986**, 27, 4549-4552.
- (2) Klegraf, E.; Follmann, M.; Schollmeyer, D.; Kunz, H. *Eur. J. Org. Chem.* **2004**, 3346-3360.
- (3) Turunen, B. J.; Georg, G. I. *J. Am. Chem. Soc.* **2006**, 128, 8702-8703.
- (4) Guerry, P.; Neier, R. *Synthesis* **1984**, 485-488.
- (5) Jones, T. N.; McClure, C. K. *Synlett* **2009**, 1289-1290.









1b3209-Jul10 2 1 C:\Bruker\TOPSPIN leibi






1b


lb4285 1 1 C:\Bruker\TOPSPIN leibi











1b



lb4285 2 1 C:\Bruker\TOPSPIN leibi



































1bMar03-COOPh 1 1 C:\Bruker\TOPSPIN leibi









1bMar03-COOPh 2 1 C:\Bruker\TOPSPIN leibi






















































lbDec06-coupling-Br 20 1 C:\Bruker\TOPSPIN leibi














1b5029 1 1 C:\Bruker\TOPSPIN bixxx018










lb4293-coupling 1 1 C:\Bruker\TOPSPIN leibi






lb4293-coupling 2 1 C:\Bruker\TOPSPIN leibi







lb4271-OTBS 1 1 C:\Bruker\TOPSPIN bixxx018










lb4271-OTBS 2 1 C:\Bruker\TOPSPIN bixxx018







lb5051 2 1 C:\Bruker\TOPSPIN bixxx018

